{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T23:06:44Z","timestamp":1779577604899,"version":"3.53.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100032799","name":"Centre Henri Becquerel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008381","name":"Institut Claudius Regaud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejso.2026.111768","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:54:00Z","timestamp":1774425240000},"page":"111768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database"],"prefix":"10.1016","volume":"52","author":[{"given":"Sophie","family":"Le Bars","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-4314","authenticated-orcid":false,"given":"Catherine","family":"Guerin-Charbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-8971","authenticated-orcid":false,"given":"Elodie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9516-9797","authenticated-orcid":false,"given":"Quentin Dominique","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Costaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pomel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7685-6070","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Narducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3875-4011","authenticated-orcid":false,"given":"Enora","family":"Laas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5330-4479","authenticated-orcid":false,"given":"L\u00e9a","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-3953","authenticated-orcid":false,"given":"Eric","family":"Lambaudie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rouzier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-9719","authenticated-orcid":false,"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"De La Motte Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-9425","authenticated-orcid":false,"given":"Lise","family":"Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Classe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7005-5785","authenticated-orcid":false,"given":"C\u00e9cile","family":"Loaec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.ejso.2026.111768_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int J Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.ejso.2026.111768_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ejso.2026.111768_bib3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.111768_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynecol Obstet"},{"issue":"9, Supplement 1","key":"10.1016\/j.ejso.2026.111768_bib6","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0007-4551(21)00582-8","article-title":"Traitement m\u00e9dical de premi\u00e8re ligne du cancer \u00e9pith\u00e9lial de l\u2019ovaire de haut grade: first-line medical treatment of high-grade epithelial ovarian cancer","volume":"108","author":"Selle","year":"2021","journal-title":"Bulletin du Cancer 1 d\u00e9c"},{"issue":"5","key":"10.1016\/j.ejso.2026.111768_bib7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.ejso.2026.111768_bib8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejso.2026.111768_bib9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejso.2026.111768_bib10","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejso.2026.111768_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2026.111768_bib12","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","article-title":"Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer","volume":"19","author":"Chang","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111768_bib13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cancers12030768","article-title":"30 years of experience in the management of stage III and IV epithelial ovarian cancer: impact of surgical strategies on survival","volume":"12","author":"Delga","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejso.2026.111768_bib14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2026.111768_bib15","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane gynaecological, Neuro-oncology and orphan cancer group, \u00e9diteur","volume":"2016","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ejso.2026.111768_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2010.07.032","article-title":"Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. Single institution experience","volume":"119","author":"Peiretti","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.111768_bib17","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2026.111768_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ygyno.2019.02.019","article-title":"The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review","volume":"153","author":"Timmermans","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111768_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111768_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2021.07.019","article-title":"Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: analysis of the French national ESME-unicancer database","volume":"163","author":"De Nonneville","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.111768_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2016.05.025","article-title":"Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - a population-based cohort study","volume":"142","author":"Dahm-K\u00e4hler","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.111768_bib22","series-title":"Peritoneal carcinomatosis: principles of management","first-page":"466","author":"Sugarbaker","year":"1996"},{"issue":"9","key":"10.1016\/j.ejso.2026.111768_bib23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N Engl J Med 28 f\u00e9vr"},{"issue":"9, Supplement 1","key":"10.1016\/j.ejso.2026.111768_bib24","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0007-4551(21)00583-X","article-title":"Prise en charge chirurgicale du cancer \u00e9pith\u00e9lial de l\u2019ovaire \u2013 premi\u00e8re ligne et premi\u00e8re rechute: surgical management of epithelial ovarian cancer \u2013 first line and first relapse","volume":"108","author":"Classe","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ejso.2026.111768_bib25","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e69","article-title":"Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis","author":"Caruso","year":"2022","journal-title":"J Gynecol Oncol"},{"issue":"17_suppl","key":"10.1016\/j.ejso.2026.111768_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5505","article-title":"Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: the CARACO phase III randomized trial","volume":"42","author":"Classe","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9, Supplement 1","key":"10.1016\/j.ejso.2026.111768_bib27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0007-4551(21)00581-6","volume":"108","author":"Joly","year":"2021","journal-title":"Bull Cancer"},{"issue":"8","key":"10.1016\/j.ejso.2026.111768_bib28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/dji102","article-title":"Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial","volume":"97","author":"Panici","year":"2005","journal-title":"JNCI (J Natl Cancer Inst):"},{"issue":"23","key":"10.1016\/j.ejso.2026.111768_bib29","doi-asserted-by":"crossref","first-page":"37807","DOI":"10.18632\/oncotarget.13696","article-title":"Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: reappraisal in the era of radical surgery","volume":"8","author":"Eoh","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ejso.2026.111768_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3802\/jgo.2015.26.4.303","article-title":"Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients","volume":"26","author":"Iwase","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.111768_bib31","article-title":"Role of lymphadenectomy during interval debulking surgery performed after neoadjuvant chemotherapy in patients with advanced ovarian cancer","author":"He","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111768_bib32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejso.2012.12.006","article-title":"Defining the optimal lymphadenectomy cut-off value in epithelial ovarian cancer staging surgery utilizing a mathematical model of validation","volume":"39","author":"Pereira","year":"2013","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111768_bib33","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.3802\/jgo.2020.31.e67","article-title":"Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis","volume":"31","author":"Chiyoda","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.111768_bib35","first-page":"118","article-title":"Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: a memorial sloan kettering cancer center team ovary study. Gynecol oncol","volume":"169","author":"Ehmann","year":"2023","journal-title":"f\u00e9vr"},{"issue":"3","key":"10.1016\/j.ejso.2026.111768_bib36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ygyno.2014.10.003","article-title":"Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer","volume":"135","author":"Ataseven","year":"2014","journal-title":"Gynecol Oncol d\u00e9c"},{"issue":"1","key":"10.1016\/j.ejso.2026.111768_bib37","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.3802\/jgo.2018.29.e12","article-title":"Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish gynecologic oncology group study","volume":"29","author":"Ayhan","year":"2018","journal-title":"J Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2026.111768_bib38","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1245\/s10434-015-5069-z","article-title":"Surgical complexity impact on survival after complete cytoreductive surgery for advanced ovarian cancer","volume":"23","author":"Martinez","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.111768_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2023.101014","article-title":"Prognostic role of the peritoneal cancer index in ovarian cancer patients who undergo cytoreductive surgery: a meta-analysis","volume":"47","author":"Yang","year":"2023","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.111768_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejso.2017.11.003","article-title":"Prognostic value of peritoneal cancer index in primary advanced ovarian cancer","volume":"44","author":"Llueca","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2026.111768_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258783","article-title":"Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: a multicentre study from the FRANCOGYN group","volume":"16","author":"Mimoun","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejso.2026.111768_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13014-019-1381-2","article-title":"Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study","volume":"14","author":"Arians","year":"2019","journal-title":"Radiat Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2026.111768_bib43","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","article-title":"Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab\u2019)2--a phase I study","volume":"50","author":"Andersson","year":"2009","journal-title":"J Nucl Med juill"},{"key":"10.1016\/j.ejso.2026.111768_bib44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nucmedbio.2017.01.003","article-title":"B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models","volume":"47","author":"Kasten","year":"2017","journal-title":"Nucl Med Biol avr"},{"issue":"4","key":"10.1016\/j.ejso.2026.111768_bib45","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2967\/jnumed.123.266524","article-title":"Interrogating the theranostic capacity of a MUC16-Targeted antibody for ovarian cancer","volume":"65","author":"Mack","year":"2024","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.ejso.2026.111768_bib46","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1078-0432.CCR-21-1798","article-title":"ImmunoPET of ovarian and pancreatic cancer with AR9.6, a novel MUC16-Targeted therapeutic antibody","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326003872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326003872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T22:58:42Z","timestamp":1779577122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326003872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0748798326003872"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111768","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111768"}}